Takeda, Amgen To Do New Phase III Trial Of Motesanib Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals and U.S.-based Amgen have decided to make a new try to get their motesanib cancer drug through clinical trials. The drug designed to treat non-squamous non-small cell lung cancer, was pulled late last year when the death rate of participants in a Phase III trial became too high. The firms decided to try again after an independent monitoring committee recommended the move. An Amgen executive said the firm believes it has the correct patient population this time. (Click here for more